Chapter 27: Drugs Affecting Bone Metabolism

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So every 10 years, your body just builds you an entirely new skeleton.

Yeah, it's about 10 % of your bone mass completely replaced every single year.

Which is wild!

Just this constant ongoing cellular demolition and reconstruction.

Exactly.

But, you know, what happens when that demolition crew starts working faster than the builders?

Right.

And what if the pharmacological weapons we use to stop that rogue demolition end up physically trapped inside your bone matrix?

Permanently booby trapping your skeleton for decades.

I mean, it completely changes how you look at a skeleton, doesn't it?

Oh, absolutely.

It isn't just this static scaffold holding you up.

It is a highly active, honestly, a highly volatile chemical battleground.

Well, welcome to a custom tailored deep dive aimed directly at you.

Yes, you, the college student gearing up for a massive pharmacology exam.

We feel your pain.

We really do.

So today, our sole mission is to conquer Chapter 107 of Lippincott Illustrated Reviews, Pharmacology the seventh edition.

The chapter is Drugs Affecting Bone Metabolism.

But look, we aren't just going to read you a list of drug names that sound like, you know, alien species.

No, no, we are treating this like an escalating arms race.

We're going to trace the exact logical connections from the foundational physiology of your skeleton to providing the raw materials to poisoning the rogue cell.

Intercepting their communications.

Right.

And finally, forcing the body to actually rebuild.

Because by the time we're done here, you will understand the underlying why behind the drug targets.

Yeah.

The mechanisms of action, the clinical adverse effects, it'll all make sense.

But you won't have to rely purely on rote memorization because the entire pharmacological progression follows this clear logic.

Exactly.

So since we know the primary issue we're treating is driven by a cellular imbalance, we should probably establish the baseline.

Yeah, let's start there.

I mean, we all know the basic players from Anatomy, right?

You've got the osteoclasts.

Those are the demolition crew breaking down old bone in a process called resorption.

Resorption.

Right.

And then the osteoblasts act as the builders synthesizing the new matrix.

And the most critical part of that building phase is the bone mineralization.

Oh, the crystals.

Right.

Yeah.

The osteoblasts deposit these crystals of calcium phosphate specifically, and you should know this name, hydroxyapatite, right into the newly synthesized bone.

Hydroxyapatite.

That's the stuff.

That hydroxyapatite is what actually gives your skeleton its mechanical strength.

You know, Lippincott has this incredible electron microscope image in the chapter.

It's figure 27 .2, and it compares a normal bone matrix to an osteoporotic one.

Oh, that visual is so striking.

It really is.

You look at it, and the entire pathology we're trying to treat just clicks into place.

Like the normal bone looks like a thick, densely interconnected, sturdy sponge.

Yeah, and then you look at the osteoporotic bone, and it's just, it's frayed.

Frayed and completely hollowed out.

There are these massive gaping holes where the structural integrity has completely collapsed.

And why?

Because osteoclast resorption has just vastly outpaced osteoblast formation.

Right.

And, you know, the text does touch briefly on pageant disease, which is this localized disorder causing disorganized, misshapen bones, and osteomalacia, which is bone softening from vitamin D deficiency.

Known as rickets in kids.

Exactly.

But the undisputed focus of this material is osteoporosis.

We are talking about progressive, systemic loss of bone mass and skeletal fragility.

Systemic being the key word there.

When a patient's structural sponge develops those massive microscopic holes, the very first line of pharmacological defense has to be ensuring the body actually possesses the raw materials.

To tip the scales back toward building.

Right.

We need adequate dietary intake or supplementation of calcium and vitamin D.

Okay, let's unpack this though, because taking a calcium supplement isn't just about swallowing a pill.

Not at all.

If we want that calcium to actually reach the bone, we have to get it absorbed into the bloodstream first.

I think of it like an exclusive nightclub.

You know, the calcium is stuck outside the velvet rope waiting to get in.

That's a fun analogy.

Let's make it a bit more biochemically accurate for your exam though.

Go for it.

Think of vitamin D as the specific biochemical key that unlocks the transport proteins in your gut lining.

Ah, okay.

Yeah.

Without adequate vitamin D, your intestinal epithelial cells simply do not manufacture the calcium binding proteins needed to physically ferry that calcium from your digestive tract across the membrane and into your bloodstream.

Oh, wow.

Which is why the text emphasizes treating older patients for vitamin D deficiency first, using either vitamin D2, that's ergocalciferol, or vitamin D3, chocalciferol.

Right.

But even with the transport proteins unlocked, the specific formulation of the calcium supplement matters immensely for absorption.

It does.

And the text specifically contrasts two formulations that you absolutely need to know for the test.

First up is calcium carbonate.

The cheap one.

The cheap one, yeah.

It packs a heavy punch containing 40 % elemental calcium.

However, it has a major catch.

Calcium carbonate strictly requires an acidic environment to dissolve.

So a patient absolutely must take it with a meal, right?

So their stomach is actively producing acid.

Precisely.

If they take it on an empty stomach or if they're taking a proton pump inhibitor that suppresses stomach acid.

They're absorbing practically nothing.

Exactly.

Now, the alternative formulation is calcium citrate.

Which is different how?

Well, it only contains 21 % elemental calcium.

So they have to take way more pills to get the same dose.

Right.

But its absorption is completely independent of stomach acid.

It can be taken on an empty stomach and generally causes far less GI distress, gas and bloating.

Okay.

So providing those raw materials is crucial.

But before we move on to the heavier chemical weapons, we have to look at the other side of the prevention coin.

The drugs that cause bone loss.

Figure 27 .3 lays out a highly testable list of drugs that actively contribute to bone loss.

Because sometimes, I mean, the best pharmacological intervention is just stopping a medication that's actively causing the disease.

For sure.

The table lists several culprits.

Aluminum antacids, anticonvulsants like phenytoin, and those proton pump inhibitors we just mentioned.

But there is one massive glaring risk factor every pharmacology student must memorize.

Glucocorticoids.

Yes.

If you see a test question about a patient with rheumatoid arthritis or severe asthma who has been on daily prednisone, alarm bells should be ringing for secondary osteoporosis.

And the clinical parameter defined in the text is very specific here.

A patient taking a glucocorticoid at a dose of five milligrams a day or more for a duration of three months or longer, that's a massive risk of developing osteoporosis.

Wow.

Five milligrams for three months.

Why is it so destructive?

Well, glucocorticoids directly inhibit osteoblast formation and increase osteoclast lifespan.

Oh, man.

So you are essentially extending the demolition cruise contract while actively firing all the builders.

That is exactly what's happening.

We also need to note that calcium itself is highly reactive in the gastrointestinal tract, like it loves to bind to other drugs and form these insoluble complexes.

It's very needy that way.

Yeah.

So if a patient takes their calcium supplement at the exact same time as their iron preparations or their thyroid replacement, like levothyroxine, or even certain antibiotics like fluoroquinolones and tetracyclines.

Yeah, calcium just binds right to them, and neither drug gets absorbed.

So they're getting zero benefit.

You have to separate the administration of calcium and those specific interacting drugs by several hours to ensure bioavailability.

Okay.

So let's say we've optimized their calcium, we've unlocked the gut with vitamin D and removed any offending drugs, but it isn't enough.

The patient crosses the clinical threshold.

Right, into full -blown osteoporosis, which the text defines as having a bone mineral density 2 .5 standard deviations below a healthy young adult, or a history of an osteoporotic fracture.

Yeah, at that point, supplying raw materials just isn't going to fix those gaping holes in the bone matrix.

So what is our first major escalation?

Well, if the osteoclasts are actively destroying the structural integrity, our first strategic escalation is to poison the demolition crew.

I love that.

This brings us to the preferred first -line agents for treating post -menopausal osteoporosis.

The bisphosphonates.

The dronates, like elendronate, risedronate, and zoledronic acid.

Those are the ones.

The mechanism of action here is brilliant.

It isn't just floating through the bloodstream hoping to bump into an osteoclast, right?

It specifically booby traps the worksite.

That's a really great way to conceptualize it.

Bisphosphonates have this massive chemical affinity for those hydroxyapatite crystals we talked about earlier.

In the bone.

Right.

When administered, they travel to the skeleton and permanently bind directly to the bone matrix itself, and they just sit there.

Just waiting.

Just waiting.

Later, when an osteoclast arrives and secretes acid to start resorbing that specific section of bone, the acidic environment releases the bisphosphonate.

So the osteoclast basically ingests the poison it just dug up.

Exactly.

It ingests the drug, which then immediately shuts down critical intracellular enzymes, decreasing osteoclastic activity, and ultimately promoting osteoclast apoptosis.

Program cell death.

Yep.

The demolition crew poisons themselves just by doing their job.

But, and this is a big but, delivering that poison to the bone matrix is a pharmacokinetic nightmare.

When you look at the tables in figures 27 .5 and 27 .6, the oral bioavailability of these drugs is shockingly low.

It is less than 1%.

Less than 1%.

Yeah.

After a patient swallows a tablet of elendronate, less than 1 % of that active drug actually makes it into the bloodstream.

Because the absorption is so incredibly fragile,

right?

Like any interference drops that 1 % down to a flat zero?

Which leads to the famously rigid dosing instructions you will definitely be tested on.

Oh yeah, let's go through these.

Patients must take oral bisphosphonates on a completely empty stomach, with 6 to 8 ounces of plain water only.

No coffee, no juice, no mineral water.

None of it.

Then, they have to fast no food, no drinks, no other medications, for at least 30 minutes.

And for bengenate, that waiting period is a full 60 minutes, right?

Exactly.

And waiting isn't the only rule.

They have to remain perfectly, strictly upright for that entire 30 to 60 minute duration.

No lying down, no reclining on the couch to watch TV.

Why this strict posture check?

I mean, why does gravity matter so much here?

Because oral bisphosphonates are incredibly caustic to mucosal tissue.

They are notorious for causing severe esophagitis and esophageal ulcers.

Oh yikes.

Yeah, if that pill or the dissolved medication sits in the esophagus or reflexes back up through the lower esophageal stincter, it causes severe localized tissue damage.

Remaining perfectly upright enlists gravity to ensure the drug clears the esophagus entirely and enters the stomach safely.

That makes sense.

But man, if a patient has severe erosive esophagitis or simply cannot tolerate those strict oral rules.

The text highlights intravenous alternatives, like Avibandrinate or Zoledronic acid.

And speaking of Zoledronic acid, let's examine the anti -resorptive activity table in figure 27 .6.

It perfectly illustrates how far pharmacologists have pushed this specific mechanism.

It really tracks the historical arms race of the drug class.

The table sets the baseline potency with an older first generation bisphosphonate, edidrinate.

It assigns it a relative anti -resorptive activity of 1.

Okay, baseline of 1.

From there, the potency scales dramatically.

Pimidrinate has an activity of 100.

Alendrinate sits at 1 ,000.

Rizodrinate is 5 ,000.

And at the absolute pinnacle, you have Avibandrinate and Zoledronic acid, both engineered to have an anti -resorptive activity of 10 ,000 times the baseline.

10 ,000 times.

Which is exactly why Zoledronic acid is powerful enough to be administered as an intravenous infusion just once a single year.

Once a year.

And this is where we get back to that booby trap idea, engineering a drug to permanently embed in the skeleton and freeze bone remodeling at 10 ,000 times the normal potency.

That comes with some severe long -term consequences, doesn't it?

It does.

While common side effects are transient things like, you know, diarrhea, abdominal pain, and musculoskeletal pain, freezing the bone turnover process introduces two rare but devastating risks.

Osteonecrosis of the jaw and atypical femur fractures.

Wait, if the entire goal of the drug is to increase bone mass and prevent fractures, how does it cause a femur fracture?

That sounds completely backward.

It seems paradoxical until you remember the physiological purpose of bone remodeling.

Right.

That 10 % turnover every year isn't just for calcium homeostasis.

It repairs microscopic wear and tear.

Oh, so if you completely freeze the remodeling process with high -potency bisphosphonates for years on end.

The osteoclasts can't clear away the accumulated micro -damage.

The bone becomes denser, yes, but it also becomes brittle.

So a patient could just be walking down the street and their femur snaps because years of unrepaired microstress finally gave way.

And osteonecrosis of the jaw follows a similar logic.

It's often triggered by a dental extraction.

The jawbone is exposed and needs to heal, but the osteoclasts are poisoned.

The bone can't remodel, the tissue dies, and the bone becomes necrotic.

Wow.

Because of these risks, current clinical guidelines strongly recommend a drug holiday.

Yes.

You take them off the drug to let the bone wake up and clear the damage,

usually after five years of oral bisphosphonates or three years of zoledronic acid.

And that drug holiday is possible precisely because the bisphosphonates remain bound to the hydroxyapatite for years, right, continuing to exert mild anti -resorptive effects even after the active dosing starts.

Exactly.

They just hang around.

But if bisphosphonates carry the risk of brittle femurs and necrotic jawbones because they permanently embed in the matrix, it seems like a really messy long -term solution.

It's definitely a blood instrument.

Right.

So why haven't pharmacologists found a way to just intercept the chemical signals so the rogue osteoclasts never even show up to the worksite in the first place?

Oh, they did.

And it's a completely different battle strategy.

Enter dinosumab.

Dinosumab.

You can immediately identify its strategy by the dunmab suffix, which tells you it is a monoclonal antibody.

Right on the money.

So instead of a tiny chemical poison embedding in the bone, this is a large engineered immune protein floating in the circulation.

What is it targeting?

Dinosumab specifically targets and neutralizes a protein called RNAL.

That stands for Receptor Activator of Nuclear Factor Kappa -B -Ligand.

That's a mouthful.

RNL.

You're right, Karan -L.

In healthy physiology, RN -Kolel is the chemical signal secreted by osteoblasts that binds to rank receptors on osteoclast precursors, stimulating them to mature, function, and survive.

So RN -Kolel is like the physical authorization order telling the demolition crew to assemble and start digging.

Exactly.

And dinosumab binds to RN -Kolel in the bloodstream, intercepting it before it can ever reach the osteoclast precursor.

Oh, that's so smart.

By inhibiting RN -Kolel, dinosumab literally stops osteoclast formation before it begins.

The demolition crew is never assembled.

And because it operates in the bloodstream rather than binding to bone, its dosing has to be totally different.

Very different.

It's administered via subcutaneous injection every six months.

It's considered a first -line agent, especially for postmenopausal women, at high risk of fracture.

But because it's an antibody tinkering with immune -adjacent signaling pathways, the adverse effect profile must shift.

It does.

It has been associated with an increased risk of infections and dermatological reactions.

It can also cause severe hypocalcemia.

Makes sense.

And interestingly, despite having a completely different mechanism of action than bisphosphonates, because it also profoundly suppresses bone remodeling, it still carries those rare risks of osteonecrosis of the jaw and atypical femur fractures.

Wow.

So you can't escape the side effects of freezing remodeling no matter how you do it.

Biology always demands a trade -off.

Okay.

So up until this point, whether we are poisoning them with bisphosphonates or intercepting their orders with dinosumab, the strategy has been entirely defensive.

We are just stopping the osteoclasts.

Signing defense, yeah.

But what if a patient has incredibly severe bone loss?

Can we stop playing defense and force our osteoblasts to go on offense and actually build new bone?

We can, using parathyroid agents.

The text introduces two specific drugs, teraparotide, which is a combinent form of human parathyroid hormone, and ablaparotide, an analog of parathyroid hormone -related peptide.

No, wait.

If you remember basic endocrine physiology, that should sound completely counterintuitive.

Oh, totally backwards.

Naturally occurring parathyroid hormone is secreted when blood calcium is low.

Its entire job is to increase osteoclast activity to break down bone and release calcium into the blood.

How can a parathyroid hormone analog be a bone builder?

It is one of the most fascinating paradoxes in pharmacology.

Continuous high levels of parathyroid hormone, like you would see in hyperparathyroidism, absolutely cause bone resorption.

But pharmacologically, we don't give it continuously.

We give it intermittently.

Exactly.

These drugs are administered as a once -daily subcutaneous injection.

This intermittent, pulsatile exposure to the parathyroid hormone receptor uniquely stimulates osteoblastic activity and prolongs osteoblast survival.

So it actively increases bone formation and structural strength.

Yep.

They're the only true builders in the entire chapter.

But the text puts massive clinical guardrails around them.

They are strictly reserved for patients at a very high risk of fracture who have either failed or cannot tolerate other osteoporosis therapies.

Which seems weird, right?

Yeah.

If they're the only drugs that actually build bone, why hold them back as a last resort?

Because manipulating the parathyroid pathway to rapidly synthesize cellular growth comes with severe risks.

Along with hypercalcemia and orthostatic hypotension, teraparotide and abilaparotide have been shown to cause an increased incidence of osteosarcoma, a highly aggressive bone cancer, in rat models.

Osteosarcoma.

That is a terrifying adverse effect profile.

It is.

Because of that specific risk of osteosarcoma, cumulative lifetime use is strictly capped.

A patient cannot use either of these agents for more than two years total in their entire life.

Two years...ever?

Ever.

It is a short, intense, tightly controlled burst of building, and then you must transition them to an anti -resorptive agent to maintain the new bone.

Wow.

Okay, so we have raw materials, bone poisons, communication interceptors, and intense bone builders.

To round out the chapter's pharmacological arsenal, we need to look at leveraging the body's natural endocrine regulators.

The hormones.

Right.

The text clearly states that the dramatic drop in estrogen after menopause promotes osteoclast survival and causes a rapid decline in bone mass.

So why don't we just prescribe widespread estrogen replacement therapy to protect every post -menopausal woman's skeleton?

Well, it comes down to a strict risk versus reward calculation.

Estrogen replacement is undeniably effective for preventing post -menopausal bone loss.

However, unopposed, straight estrogen therapy systemically activates estrogen receptors everywhere.

Everywhere in the body.

Right.

And this heavily increases the risk of endometrial cancer unless the woman is also taking a progestin, and it increases the risk of breast cancer, deep vein thrombosis, pulmonary embolisms, and stroke.

So the systemic risks far outweigh the skeletal rewards.

For most patients, yes.

But pharmacologists realized they didn't have to activate every estrogen receptor in the body.

They engineered CIRM's selective estrogen receptor modulators.

And the specific drug you need to know for the exam is Riloxafine.

Riloxafine is fascinating.

It's chemically engineered to exploit the fact that estrogen receptors actually fold differently depending on the tissue they are located in.

Oh really?

Yeah.

In the bone, Riloxafine acts as an estrogen agonist.

It perfectly mimics natural estrogen, increasing bone density, and promoting osteoclast apoptosis.

But in the breast and the uterus?

In breast and endometrial tissue, the receptor folds differently when Riloxafine binds to it, causing the drug to act as an estrogen antagonist.

It actively blocks estrogen effects.

So you gain the bone -building benefits of estrogen without the increased risk of endometrial cancer?

In fact, it actually decreases the risk of invasive breast cancer.

It sounds like the perfect compromise, but the text notes it isn't a miracle drug, right?

No.

It hasn't been shown to reduce non -vertebral or hip fractures quite as effectively as bisphosphonates or dinosumab.

And because it still interacts with the estrogen pathways in the blood and hypothalamus, it still carries a significant risk of venous thromboembolism, and it frequently causes hot flashes and leg cramps.

So it serves as an alternative preventive therapy, particularly useful for women who need osteoporosis prevention and also have a high risk of breast cancer.

Exactly.

It's a very targeted tool.

And finally, the text covers one last hormonal approximator, Salmon Calcitonin.

Ah, Salmon Calcitonin.

Well, Calcitonin naturally opposes parathyroid hormone to reduce bone resorption.

However, the Salmon -derived pharmacological version is considered significantly weaker than every other agent we've discussed.

So it's kind of old news.

Yeah, it is no longer routinely recommended for standard osteoporosis treatment.

But you still need to know it for the exam.

You do.

Because it possesses one highly specific, highly testable superpower.

It does.

When administered as an intranasal spray, Calcitonin has a unique unexplained analgesic property.

It uniquely relieves the specific bone pain associated with a recent painful osteoporotic vertebral fracture.

So while it won't fix the underlying disease as well as a bisphosphonate, it is sometimes prescribed for short -term pain management in that exact scenario.

Right.

Though being a nasal spray, it frequently causes rhinitis or a runny nose.

Naturally.

Well, with that, you have the complete picture.

You understand the structural collapse caused by osteoclasts outpacing osteoblasts.

You know why calitin carbonate needs a meal while citrate doesn't.

You understand how bisphosphonates track the matrix, how dinosumab cuts the communication lines, why teraperitide builds bone but is capped at two years, and how reloxapine selectively plays both sides of the estrogen receptor.

You now have the underlying logic.

You don't have to blindly memorize the strict, upright dosing rules of lindrinate if you know it causes erosive esophagitis.

It all connects.

Connecting the physiology directly to the adverse effects really is the absolute best way to succeed in pharmacology.

It saves you so much time.

Before you close your textbook and take a well -deserved break, let's circle back to that thought we started with.

We use these powerful agents to shift the balance of a skeleton that completely replaces itself every 10 years.

When you administer a drug like zoledronic acid and it irreversibly binds to the hydroxyapatite crystals,

it becomes a permanent part of the patient's architecture.

It really makes you appreciate just how profoundly pharmacology alters human physiology at the most foundational microscopic level.

We aren't just treating a condition, we are fundamentally restructuring the material they are made of.

Exactly.

On behalf of the Last Minute Lecture Team, thank you for letting us guide you through this material.

Good luck on your exam and keep learning.